Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: RLFTY )

5.976 UNCHANGED
Streaming Delayed Price Updated: 11:58 AM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about RLFTY

< Previous 1 2 3 4 Next >
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (Sodium Phenylbutyrate) New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders (UCDs)
GENEVA, SWITZERLAND / ACCESSWIRE / July 18, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief), today announced that its collaboration partner, ACER Therapeutics, Inc.... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures Product Safety
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine
Experienced Leader in Commercial and Medical Affairs, With a Focus on Gene Therapy, to Spearhead Relief's New Strategic Foray Into Genetic Medicine 
From Relief Therapeutics Holdings AG
Via AccessWire
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU
Company acquires an additional therapeutic product for the management of patients with PKU for worldwide markets, with the exception of the United Kingdom, thereby complementing and enhancing its... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures Product Safety
Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has filed Amendment No. 4 to its Registration... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk
GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
GENEVA, SWITZERLAND / ACCESSWIRE / June 17, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), announced today that it has filed Amendment No. 3 to its Registration... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil
GENEVA, SWITZERLAND / ACCESSWIRE / June 13, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures Product Safety
Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target Action Date for ACER-001
GENEVA, SWITZERLAND / ACCESSWIRE / June 8, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures Product Safety
Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
GENEVA, SWITZERLAND / ACCESSWIRE / June 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (" Relief " or the " Company "), a biopharmaceutical company seeking to provide patients... 
From Relief Therapeutics Holdings AG
Via AccessWire
Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U.S. National Institutes of Health (NIH) Study of Intravenous Aviptadil in Critical COVID-19 Patients
GENEVA, SWITZERLAND / ACCESSWIRE / May 31, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19
GENEVA, SWITZERLAND / ACCESSWIRE / May 26, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF), (OTCQB:RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief Therapeutics Expands U.S. Commercial Team
Tracy Truong and Kelli Powell Appointed Regional Clinical Specialists for the West and Northeast Regions, RespectivelySeasoned Account Managers Bring Extensive Pharmaceutical Sales Experience in Rare... 
From Relief Therapeutics Holdings AG
Via AccessWire
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
GENEVA, SWITZERLAND / ACCESSWIRE / May 11, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (" Relief "), announced today that it has filed Amendment No. 2 to its Registration... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Relief Therapeutics to Participate in Industry and Investor Conferences in May
GENEVA, SWITZERLAND / ACCESSWIRE / May 9, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / May 6, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY)... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures Product Safety
Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
GENEVA, SWITZERLAND / ACCESSWIRE / May 6, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTY) ("Relief" or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)
Notice of Allowance of Patent Application for Modified Release Orally Administered Amino Acid Formulations, Strengthens Proprietary Position in U.S. until 2036 GENEVA, SWITZERLAND / ACCESSWIRE / April... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing
Proven Pharmaceutical Marketing Leader Brings Extensive Experience in Rare Diseases, Digital Innovation and New Product Launches to Relief's U.S. Commercial Team GENEVA, SWITZERLAND / ACCESSWIRE /... 
From Relief Therapeutics Holdings AG
Via AccessWire
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil in a Subgroup of Patients with Critical COVID-19 with Respiratory Failure that... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / April 12, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA... 
From Relief Therapeutics Holdings AG
Via AccessWire
Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process
GENEVA, SWITZERLAND / ACCESSWIRE / April 5, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), today reported that it has entered into a stipulation to stay the... 
From Relief Therapeutics Holdings AG
Via AccessWire
Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
GENEVA, SWITZERLAND / ACCESSWIRE / April 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19
GENEVA, SWITZERLAND / ACCESSWIRE / April 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Reports Full-Year 2021 Results and Provides Corporate Update
GENEVA, SWITZERLAND / ACCESSWIRE / March 31, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Relief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKU
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports In Vivo Data Published in the Peer Reviewed, International Journal of Molecular Sciences, Indicating Prolonged Release... 
From Relief Therapeutics Holdings AG
Via AccessWire
Relief Receives Trademark Registration for RLF-100(R) From the U.S. Patent and Trademark Office
GENEVA, SWITZERLAND / ACCESSWIRE / March 24, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales
Proven Pharmaceutical Sales Professional Brings Big Pharma Experience to Relief's U.S. Expansion Activities GENEVA, SWITZERLAND / ACCESSWIRE / March 21, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF,... 
From Relief Therapeutics Holdings AG
Via AccessWire
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
GENEVA, SWITZERLAND / ACCESSWIRE / March 21, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY)("Relief"), announced today that it has filed Amendment No. 1 to its Registration... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients
Despite Primary Endpoint not Being Met, Due to Small Sample Size, Results Show a Very Positive Trend in Efficacy Parameters with a Clean Safety and Tolerability Profile GENEVA, SWITZERLAND / ACCESSWIRE... 
From Relief Therapeutics Holdings AG
Via AccessWire
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU
Company Signs Binding Term Sheet to Acquire Worldwide Commercialization Rights, Except in the United Kingdom Expands on Existing PKU GOLIKE(R) Portfolio of Products GENEVA, SWITZERLAND / ACCESSWIRE /... 
From Relief Therapeutics Holdings AG
Via AccessWire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.